In last trading session, Spyre Therapeutics Inc (NASDAQ:SYRE) saw 0.79 million shares changing hands with its beta currently measuring 2.98. Company’s recent per share price level of $21.29 trading at -$1.12 or -5.00% at ring of the bell on the day assigns it a market valuation of $1.25B. That closing price of SYRE’s stock is at a discount of -125.32% from its 52-week high price of $47.97 and is indicating a premium of 5.73% from its 52-week low price of $20.07.

For Spyre Therapeutics Inc (SYRE), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.27. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.94 in the current quarter.

Spyre Therapeutics Inc (NASDAQ:SYRE) trade information

Upright in the red during last session for losing -5.00%, in the last five days SYRE remained trading in the red while hitting it’s week-highest on Tuesday, 02/18/25 when the stock touched $21.29 price level, adding 9.79% to its value on the day. Spyre Therapeutics Inc’s shares saw a change of -8.55% in year-to-date performance and have moved -6.13% in past 5-day. Spyre Therapeutics Inc (NASDAQ:SYRE) showed a performance of -2.43% in past 30-days.

Wall Street analysts have assigned a consensus price target of 50 to the stock, which implies a rise of 57.42% to its current value. Analysts have been projecting 40 as a low price target for the stock while placing it at a high target of 71. It follows that stock’s current price would drop -87.88% in reaching the projected high whereas dropping to the targeted low would mean a loss of -87.88% for stock’s current value.

Spyre Therapeutics Inc (SYRE) estimates and forecasts

This year revenue growth is estimated to rise 162.10% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 2.33M for the same. And 5 analysts are in estimates of company making revenue of 4M in the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 23.71% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 91.35% while estimates for its earnings growth in next 5 years are of 56.88%.

Spyre Therapeutics Inc (NASDAQ:SYRE)’s Major holders

FMR LLC is the top institutional holder at SYRE for having 7.51 million shares of worth $176.51 million. And as of 2024-06-30, it was holding 16.568 of the company’s outstanding shares.

The second largest institutional holder is FAIRMOUNT FUNDS MANAGEMENT LLC, which was holding about 4.02 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.8668 of outstanding shares, having a total worth of $94.47 million.

On the other hand, Vanguard Total Stock Market Index Fund and Fidelity Growth Company Fund are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.47 shares of worth $31.33 million or 2.86% of the total outstanding shares. The later fund manager was in possession of 1.37 shares on Dec 31, 2024 , making its stake of worth around $29.14 million in the company or a holder of 2.66% of company’s stock.